Richter’s transformation (RT), also known as Richter’s syndrome or histologic transformation, is the development of an aggressive non-Hodgkin lymphoma in a patient with a history of Chronic Lymphocytic Leukemia (CLL).
Histology and Incidence
- Transformed Histologies: RT most commonly transforms into diffuse large B-cell lymphoma (DLBCL), which occurs in approximately 90% of cases. The remaining 10% of cases transform into Hodgkin lymphoma.
- Frequency: Approximately 2–16% of patients with CLL will develop RT, with an incidence rate estimated at 0.5–1% per year. The exact incidence may be under-reported due to the aggressiveness of the disease and the frequent absence of adequate biopsy samples.
Risk Factors and Genomics
The risk of developing RT increases with several clinical and genetic factors:
- Genetics: Incidence is higher in patients with complex cytogenetics, del(17p), TP53 inactivation, unmutated IGHV status, and NOTCH1 mutations.
- Clinical Factors: Increased age and a high number of prior CLL treatment regimens are associated with a higher risk.
- Early Onset with Targeted Therapy: RT tends to occur earlier in the disease course than standard CLL progression, typically within the first 1–2 years of treatment with agents like ibrutinib or zanubrutinib.
Clinical Presentation and Diagnosis
- RT is histologically more aggressive than CLL and should be suspected if a known CLL patient develops the following:
- Rapidly growing and/or asymmetrical lymphadenopathy.
- New constitutional symptoms such as fevers, drenching night sweats, or inappropriate weight loss.
- Laboratory Abnormalities: A rapidly rising lactate dehydrogenase (LDH) level, new onset cytopenias, or new hypercalcemia.
- Confirmation: A biopsy is recommended and necessary to confirm the diagnosis of RT.
Management and Prognosis
Outcome: The clinical outcome for RT is generally poor, with the disease typically being resistant to standard chemotherapy. The median survival is only 8–12 months from the time of transformation.
Treatment Paradigms:
- There are no randomized trials to establish a gold standard treatment, so therapy is generally directed toward aggressive DLBCL or Hodgkin lymphoma protocols.
- Bridging Therapy: Clinicians may consider continuing BTK inhibitors or other “bridging” therapies until the next line of treatment is initiated.
- Hematopoietic Stem Cell Transplantation (HSCT): Allogeneic HSCT has shown promising results in managing this patient population